免疫耐受
免疫系统
免疫学
微生物群
免疫抑制
生物
调节性T细胞
移植
平衡
背景(考古学)
肝移植
T细胞
医学
白细胞介素2受体
细胞生物学
生物信息学
内科学
古生物学
作者
Soon Kyu Lee,Jung Hyun Kwon,Jeong Won Jang,Si Hyun Bae,Seung Kew Yoon,Eun Sun Jung,Jong Young Choi
出处
期刊:Transplantation
[Ovid Technologies (Wolters Kluwer)]
日期:2024-10-08
标识
DOI:10.1097/tp.0000000000005220
摘要
Liver transplantation (LT) is the ultimate treatment for patients with end-stage liver disease or early hepatocellular carcinoma. In the context of LT, because of the unique immunological characteristics of human liver allograft, 5%–20% of selected LT recipients can achieve operational tolerance. Nonetheless, there remains a risk of rejection in LT patients. Maintaining immune homeostasis is thus crucial for improving clinical outcomes in these patients. In mechanism, several immune cells, including dendritic cells, Kupffer cells, myeloid-derived suppressor cells, hepatic stellate cells, regulatory B cells, and CD4 + regulatory T cells (Treg), contribute to achieving tolerance following LT. In terms of Treg, it plays a role in successfully minimizing immunosuppression or achieving tolerance post-LT while also reducing the risk of rejection. Furthermore, the gut microbiome modulates systemic immune functions along the gut–liver axis. Recent studies have explored changes in the microbiome and its metabolites under various conditions, including post-LT, acute rejection, and tolerance. Certain functional microbiomes and metabolites exhibit immunomodulatory functions, such as the augmentation of Treg, influencing immune homeostasis. Therefore, understanding the mechanisms of tolerance in LT, the role of Treg in tolerance and rejection, as well as their interactions with gut microbiome, is vital for the management of LT patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI